Company intelligence / Profile preview

LAC2βiome

Milan, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

LAC2βiome’s technology delivers live beneficial bacteria to skin using patented mixing ampoule packaging. Their first product (BiomeAge™) combines hyaluronic acid and live Lactobacilli for improved skin health, clinically validated and distributed to dispensing physicians for patient use

Therapeutic areas: Dermatology
Modalities: Live biotherapeutic product therapyMicrobial therapyBiologic
Industry: Biotech

Partnerships

Young Pharmaceuticals (exclusive US distribution)

Beyond the preview

Go deeper on LAC2βiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAC2βiome.

Explore the full profile